REDWOOD CITY, CA / ACCESSWIRE / December 7, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, has released its December 2021 CEO Shareholder Letter, which discusses recent Company milestones achieved including its financial performance, commercialization of its new Biokit, and other state-of-the-art remote cardiac monitoring devices and software apps in development.
Highlights from the shareholder letter include:
Recent uplisting to Nasdaq that the Company believes will help further attract a larger pool of sophisticated institutional investors, and a potential increase in liquidity and visibility
Commercialization of the personal medical 3-devices kit, Biokit, for integration into the Biotricity ecosystem
Record quarterly revenue of $1.81 million for its 2022 fiscal year's second quarter ended September 30, 2021, up 143% year-over-year - its tenth consecutive quarter of triple-digit year-over-year growth
The product roadmap for Bioflux®, Biotres, Biocare® Telemed, Biokit, and Bioheart
The Company's 2022 goals including launching new state-of-the-art cardiac monitoring solutions and software services.
Market Data 
Markets 
